Materialise NV (NASDAQ: MTLS) reported Q4 EPS of $0.05, in-line with the analyst estimate of $0.05. Revenue for the quarter came in at $65.68 million versus the consensus estimate of $71.8 million.

2025 Guidance

Mrs. de Vet-Veithen concluded, “For calendar year 2025, we expect our three reporting segments to evolve at a different pace. We anticipate the strongest revenue growth to come from our Materialise Medical segment. Materialise Software will continue its transition towards a cloud-based subscription business model, which will impact its revenue growth potential. Furthermore, we anticipate the difficult macroeconomic environment will persist throughout 2025, specifically in the European industrial sector, which will impact the performance of our Materialise Manufacturing segment. On a consolidated level we expect our full year revenues for 2025 to grow to a range of 270.000 to 285.000 kEUR. We will continue investing in our Materialise Medical and Software segments while keeping a strong focus on cost control and optimization in particular in our Materialise Manufacturing segment and in our corporate support departments. For calendar year 2025, we anticipate our Adjusted EBIT will reach 6.000 to 10.000 kEUR reflecting also increased depreciation charges.”

For earnings history and earnings-related data on Materialise NV (MTLS) click here.